Tak1 loss sensitizes to TRAIL-induced apoptosis in the prostate

Prostate cancer is the second deadliest noncutaneous cancer diagnosed in the western world, affecting one in six men. The five-year survival rate for prostate cancer approaches 100% if diagnosed early, but drops to ~30% if detected at an advanced stage. Many prostate cancers remain indolent. However... View More